Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Priya Jayachandran

Showing results (21-30 of 55) with videos related to

Pageof 6
Sort By:
The American Journal of Surgical Pathology|February 9, 2012
BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic featuresReetesh K Pai, Priya Jayachandran, Albert C Koong, et al.
British Journal of Cancer|October 24, 2021
Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancerHiroyuki Arai, Yi Xiao, Joshua Millstein, et al.
The Oncologist|April 6, 2023
BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint InhibitorsRaphael Colle, Sara Lonardi, Marine Cachanado, et al.
European Journal of Cancer (Oxford, England : 1990)|April 26, 2021
Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancerHiroyuki Arai, Joshua Millstein, Fotios Loupakis, et al.
Clinical Pharmacology and Therapeutics|February 13, 2026
Advancing Pharmacoequity Globally: Reflections from the ASCPT Development, Regulatory, and Outcomes NetworkPriya Jayachandran, Mayur K Ladumor, Georgios Vlasakakis, et al.
Journal of Clinical Pathology|February 15, 2015
Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancerMargaret M Kozak, Rie von Eyben, Jonathan Pai, et al.
Oncogene|July 4, 2025
Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancerPriya Jayachandran, Andrew Elliott, Shivani Soni, et al.
International Journal of Radiation Oncology, Biology, Physics|July 22, 2015
Repeat Courses of Stereotactic Radiosurgery (SRS), Deferring Whole-Brain Irradiation, for New Brain Metastases After Initial SRSDavid B Shultz, Leslie A Modlin, Priya Jayachandran, et al.
Biorxiv : the Preprint Server for Biology|May 15, 2024
Targeting circadian transcriptional programs through a cis-regulatory mechanism in triple negative breast cancerYuanzhong Pan, Tsu-Pei Chiu, Lili Zhou, et al.
Pharmaceutics|September 23, 2022
Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled AnalysisMaria Garcia-Cremades, Craig W Hendrix, Priya Jayachandran, et al.
Pageof 6

Showing results (21-30 of 55) with videos related to

Sort By:
Pageof 6
The American Journal of Surgical Pathology|February 9, 2012
BRAF-mutated, microsatellite-stable adenocarcinoma of the proximal colon: an aggressive adenocarcinoma with poor survival, mucinous differentiation, and adverse morphologic featuresReetesh K Pai, Priya Jayachandran, Albert C Koong, et al.
British Journal of Cancer|October 24, 2021
Germline polymorphisms in genes maintaining the replication fork predict the efficacy of oxaliplatin and irinotecan in patients with metastatic colorectal cancerHiroyuki Arai, Yi Xiao, Joshua Millstein, et al.
The Oncologist|April 6, 2023
BRAF V600E/RAS Mutations and Lynch Syndrome in Patients With MSI-H/dMMR Metastatic Colorectal Cancer Treated With Immune Checkpoint InhibitorsRaphael Colle, Sara Lonardi, Marine Cachanado, et al.
European Journal of Cancer (Oxford, England : 1990)|April 26, 2021
Germ line polymorphisms of genes involved in pluripotency transcription factors predict efficacy of cetuximab in metastatic colorectal cancerHiroyuki Arai, Joshua Millstein, Fotios Loupakis, et al.
Clinical Pharmacology and Therapeutics|February 13, 2026
Advancing Pharmacoequity Globally: Reflections from the ASCPT Development, Regulatory, and Outcomes NetworkPriya Jayachandran, Mayur K Ladumor, Georgios Vlasakakis, et al.
Journal of Clinical Pathology|February 15, 2015
Smad4 inactivation predicts for worse prognosis and response to fluorouracil-based treatment in colorectal cancerMargaret M Kozak, Rie von Eyben, Jonathan Pai, et al.
Oncogene|July 4, 2025
Pan-RAS inhibitors and polo-like kinase 1: promising targets in colorectal cancerPriya Jayachandran, Andrew Elliott, Shivani Soni, et al.
International Journal of Radiation Oncology, Biology, Physics|July 22, 2015
Repeat Courses of Stereotactic Radiosurgery (SRS), Deferring Whole-Brain Irradiation, for New Brain Metastases After Initial SRSDavid B Shultz, Leslie A Modlin, Priya Jayachandran, et al.
Biorxiv : the Preprint Server for Biology|May 15, 2024
Targeting circadian transcriptional programs through a cis-regulatory mechanism in triple negative breast cancerYuanzhong Pan, Tsu-Pei Chiu, Lili Zhou, et al.
Pharmaceutics|September 23, 2022
Modeling the Probability of HIV Infection over Time in High-Risk Seronegative Participants Receiving Placebo in Five Randomized Double-Blind Placebo-Controlled HIV Pre-Exposure Prophylaxis Trials: A Patient-Level Pooled AnalysisMaria Garcia-Cremades, Craig W Hendrix, Priya Jayachandran, et al.
Pageof 6